Dyadic International Inc (DYAI)
1.44
-0.03
(-2.04%)
USD |
NASDAQ |
May 02, 16:00
1.44
0.00 (0.00%)
After-Hours: 20:00
Dyadic International SG&A Expense (Quarterly): 1.652M for Dec. 31, 2023
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 1.652M |
September 30, 2023 | 1.282M |
June 30, 2023 | 1.403M |
March 31, 2023 | 1.48M |
December 31, 2022 | 1.668M |
September 30, 2022 | 1.383M |
June 30, 2022 | 1.714M |
March 31, 2022 | 1.656M |
December 31, 2021 | 1.703M |
September 30, 2021 | 1.693M |
June 30, 2021 | 1.748M |
March 31, 2021 | 1.554M |
December 31, 2020 | 1.313M |
September 30, 2020 | 1.644M |
June 30, 2020 | 1.475M |
March 31, 2020 | 1.653M |
December 31, 2019 | 1.165M |
September 30, 2019 | 1.056M |
June 30, 2019 | 1.871M |
March 31, 2019 | 1.428M |
December 31, 2018 | 1.284M |
September 30, 2018 | 1.024M |
June 30, 2018 | 0.9215M |
March 31, 2018 | 1.293M |
December 31, 2017 | 0.8796M |
Date | Value |
---|---|
September 30, 2017 | 1.127M |
June 30, 2017 | 1.234M |
March 31, 2017 | 1.790M |
December 31, 2016 | 2.029M |
September 30, 2016 | 0.8643M |
June 30, 2016 | 1.070M |
March 31, 2016 | 0.784M |
December 31, 2015 | 0.6201M |
September 30, 2015 | 1.001M |
June 30, 2015 | 1.354M |
March 31, 2015 | 0.8291M |
December 31, 2014 | 1.081M |
September 30, 2014 | 1.238M |
March 31, 2014 | 2.140M |
December 31, 2013 | 1.307M |
September 30, 2013 | 1.804M |
June 30, 2013 | 1.363M |
March 31, 2013 | 1.462M |
September 30, 2012 | 1.187M |
June 30, 2012 | 1.405M |
March 31, 2012 | 1.210M |
December 31, 2006 | 2.885M |
September 30, 2006 | 2.653M |
June 30, 2006 | 2.890M |
March 31, 2006 | 2.138M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
1.056M
Minimum
Sep 2019
1.871M
Maximum
Jun 2019
1.532M
Average
1.644M
Median
Sep 2020
SG&A Expense (Quarterly) Benchmarks
AIM ImmunoTech Inc | 10.86M |
Perspective Therapeutics Inc | 1.694M |
Protalix BioTherapeutics Inc | 4.143M |
Electromed Inc | 8.175M |
Armata Pharmaceuticals Inc | 3.179M |